

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, June 27, 2006

<b>Hide?</b>	<b><u>Set Name</u></b>	<b><u>Query</u></b>	<b><u>Hit Count</u></b>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L4	L1 and fgf	13
<input type="checkbox"/>	L3	holaday-j.in.	0
<input type="checkbox"/>	L2	holaday-jw.in.	0
<input type="checkbox"/>	L1	holaday.in.	106

END OF SEARCH HISTORY

## RESULT 1

AAB18542

ID AAB18542 standard; peptide; 44 AA.

XX

AC AAB18542;

XX

DT 15-JAN-2001 (first entry)

XX

DE Immunogenic peptide fragment derived from FGF and/or VEGF.

XX

KW Immunogenic peptide; fibroblast growth factor; FGF; VEGF; cancer;  
 KW vascular endothelial growth factor; hyperproliferative disorder;  
 KW haemangioma; solid tumour; blood borne tumour; leukaemia; metastasis;  
 KW telangiectasia; psoriasis; scleroderma; pyogenic granuloma;  
 KW myocardial angiogenesis; Crohn's disease; plaque neovascularisation;  
 KW arteriovenous malformation; corneal disease; rubeosis;  
 KW neovascular glaucoma; diabetic retinopathy; retrolental fibroplasia;  
 KW arthritis; diabetic neovascularisation; macular degeneration;  
 KW wound healing; peptic ulcer; Helicobacter related disease; fracture;  
 KW keloid; vasculogenesis; hematopoiesis; ovulation; menstruation;  
 KW placentation; cat scratch fever.

XX

OS Unidentified.

XX

PN WO200053219-A2.

XX

PD 14-SEP-2000.

XX

PF 10-MAR-2000; 2000WO-US006320.

XX

PR 11-MAR-1999; 99US-00266543.

XX

PA (ENTR-) ENTREMED INC.

XX

PI Holaday JW, Ruiz A, Madsen J;

XX

DR WPI; 2000-594263/56.

XX

PT An immunogenic composition useful for treating cancer or  
 PT hyperproliferative disorders comprises an immunogenic peptide fragment of  
 PT fibroblast growth factor and/or vascular endothelial growth factor.

XX

PS Claim 3; Page 28; 95pp; English.

XX

CC AAB18542-51 represent immunogenic peptide fragments of fibroblast growth  
 CC factor (FGF) and/or vascular endothelial growth factor (VEGF). The  
 CC peptides are used to produce immunogenic compositions. The immunogenic  
 CC composition is used for treating cancer or hyperproliferative disorders,  
 CC especially haemangioma, solid tumours, blood borne tumours, leukaemia,  
 CC metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma,  
 CC myocardial angiogenesis, Crohn's disease, plaque neovascularisation,  
 CC arteriovenous malformations, corneal diseases, rubeosis, neovascular  
 CC glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis,  
 CC diabetic neovascularisation, macular degeneration, wound healing, peptic  
 CC ulcer, Helicobacter related diseases, fractures, keloids, vasculogenesis,  
 CC hematopoiesis, ovulation, menstruation, placentation and cat scratch  
 CC fever

XX

SQ Sequence 44 AA;

Query Match 100.0%; Score 234; DB 3; Length 44;

Best Local Similarity 100.0%; Pred. No. 2.9e-25;  
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 YCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEEGVVSIKGV 44
          |||
Db      1 YCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEEGVVSIKGV 44
```